The market is dominated by low-end generic drugs
The level of drug consumption in Africa is still in the initial stage, and the main demand in the market is still concentrated in the middle and low-end generic drugs. Antibiotics, antiviral, antipyretic analgesic, anti-malaria, tuberculosis, AIDS prevention and control drugs demand. The dosage forms on the market are mainly tablets, like Ethiopia, tablets account for about 85%. Therefore, the overall structure of drug consumption level is still in an initial stage. In addition, African governments are eager to control the total cost of public health care, and there is a strong willingness to support the use of generic drugs. It can be predicted that the rapid growth of African generic drugs, especially the low-end generic drug market, will continue to maintain in the future.
Pharmaceutical products have been dependent on imports for years
According to statistics, there are about 400 drug manufacturers in sub-Saharan Africa, mainly distributed in South Africa, Nigeria, Kenya, Ghana, Ethiopia and other countries, of which the API manufacturers are almost zero. From the perspective of the development level of the pharmaceutical industry in African countries, the basic industry in North Africa and South Africa is relatively developed and has a certain pharmaceutical production capacity, and the pharmaceutical industry in east and west Africa is still in its infancy. And most of Africa’s drug factories are small and do not operate to international standards. As a result, the vast majority of pharmaceutical products in the African market are dependent on imports, with imported medicines (both prescription and over-the-counter) accounting for 70 to 90 per cent of drug consumption, and some countries rely almost entirely on imports to meet their needs. Because the pharmaceutical industry system is difficult to form in a short time, so for a long time, Africa’s medicine will mainly rely on imports.
About Wisdom Drugs
Wisdom Drugs Co .,Ltd was founded in Sep. 2011 whose headquarter located in Changzhou Creative Industry Park, having a branch in India. The company’s R&D center is engaged in not only the process development of APIs, intermediates, poly-peptide compounds and heterocyclic compounds,but also the optimization and production. We are devoted to the synthesis customization and the technology transfer, enabling compounds to be scaled from laboratory to commercial to meet the requirements of different customers.
